Citigroup Cuts Qiagen (NYSE:QGEN) Price Target to $55.00

Qiagen (NYSE:QGEN) had its price objective cut by equities research analysts at Citigroup from $55.40 to $55.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Citigroup’s price objective suggests a potential upside of 7.44% from the stock’s previous close.

A number of other equities analysts have also commented on QGEN. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. TD Cowen reiterated a “hold” rating on shares of Qiagen in a research note on Friday. Robert W. Baird set a $53.00 price target on Qiagen in a report on Friday. Jefferies Financial Group restated a “buy” rating and issued a $59.00 price objective on shares of Qiagen in a research note on Thursday. Finally, UBS Group restated a “neutral” rating on shares of Qiagen in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Qiagen has an average rating of “Hold” and a consensus target price of $54.68.

Qiagen Stock Down 0.1%

QGEN stock traded down $0.04 during midday trading on Friday, reaching $51.19. The company had a trading volume of 1,571,435 shares, compared to its average volume of 3,132,715. The company has a 50 day moving average of $49.63 and a two-hundred day moving average of $49.67. The company has a market capitalization of $10.81 billion, a P/E ratio of 25.39, a PEG ratio of 2.48 and a beta of 0.67. Qiagen has a 1 year low of $39.61 and a 1 year high of $57.81. The company has a current ratio of 2.60, a quick ratio of 2.30 and a debt-to-equity ratio of 0.45.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.01. Qiagen had a return on equity of 14.82% and a net margin of 20.33%.The business had revenue of $540.42 million during the quarter, compared to analyst estimates of $528.53 million. During the same period last year, the company earned $0.61 earnings per share. Qiagen’s quarterly revenue was up 3.6% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, equities research analysts expect that Qiagen will post 2.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Qiagen

A number of institutional investors and hedge funds have recently modified their holdings of the business. Amalgamated Bank grew its holdings in Qiagen by 1.8% during the 2nd quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock worth $565,000 after acquiring an additional 209 shares during the period. Atria Investments Inc boosted its position in shares of Qiagen by 2.9% in the 2nd quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock worth $369,000 after purchasing an additional 218 shares during the last quarter. ANTIPODES PARTNERS Ltd grew its stake in shares of Qiagen by 9.4% during the second quarter. ANTIPODES PARTNERS Ltd now owns 2,566 shares of the company’s stock worth $123,000 after purchasing an additional 221 shares during the period. Yousif Capital Management LLC increased its holdings in Qiagen by 3.7% in the second quarter. Yousif Capital Management LLC now owns 6,257 shares of the company’s stock valued at $301,000 after purchasing an additional 222 shares during the last quarter. Finally, Johnson Investment Counsel Inc. lifted its stake in Qiagen by 0.4% in the third quarter. Johnson Investment Counsel Inc. now owns 57,359 shares of the company’s stock valued at $2,563,000 after buying an additional 240 shares during the period. 70.00% of the stock is owned by institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.